BI initiates Study of Sequencing in EGFR Lung Cancer | BI US
Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.
Search
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Linagliptin Demonstrated Significant HbA1c Reduction in Elderly People With Type 2 Diabetes With Inadequate Glycemic Control
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Focus on Alliance Management
Focus on Alliance Management
US Privacy Statement
US Privacy Statement
Koropi
With its presence in Greece of more than a half century, Boehringer Ingelheim inaugurated the production facility in Koropi in 1975.
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Accountability, Agility, Intrapreneurship
How we work together
FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
Sant Cugat del Vallès (Barcelona)
Boehringer Ingelheim settled in Spain in 1952. For almost 70 years, t
The View from Both Sides of the Table
The View from Both Sides of the Table
BI & Eli Lilly & Co. Update for TRADJENTA® & JENTADUETO® | Boehringer Ingelheim US
Read about the approved updates to the PI for Tradjenta® (linagliptin) tablets and Jentadueto® (linagliptin & metformin HCI). View ISI, PI and Med Guide.
Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month
Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.
Recognized as an inclusive workplace for the fifth time
Recognized as an Inclusive Workplace for the Fifth Time
Sophia Malki: A Woman on the Rise
Sophia Malki: A Woman on the Rise
Disability Inclusion at Work: Top Score | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim receiving a 100 score with Disability:IN’s “Best Place to Work for Disability Inclusion” for the 5th year!
Women Inspiring Women: 5 questions for 6 women
Women Inspiring Women: 5 questions for 6 women
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
3 Ways Boehringer Ingelheim's Corporate Values Align with Hispanic Heritage
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Leadership
At Boehringer Ingelheim, we recognise and celebrate strong leadership. Here’s why our people love our leadership approach.
Something learnt
We know that to really thrive as a company, we have to help our teams to continue to grow in their careers. Here are some of things they have learnt at work.
Family owned
Did you know that Boehringer is still family-owned? Read this article to learn more about our culture. Check out our Careers Page for more talent insights!
Results from Phase II MASH trial announced at EASL 2024
Boehringer Ingelheim announced results from Phase II trial in metabolic dysfunction-associated steatohepatitis (MASH) at EASL 2024
PolyMast Mastitis Tube Introduced | Boehringer Ingelheim US
Find out more about the new name in the mastitis tube market, cutting down today's regular 5-day treatment to just 3: PolyMast from Boehringer Ingelheim.